Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased in Diabetes Management, driven by sales in the BGM business, favorable foreign exchange movements, and initiatives to improve unit prices and increase sales volume. In contrast, revenue declined in Diagnostics & Life Science due to stagnant market conditions, particularly in the United States. Operating profit benefited from solid sales in Diabetes Management, cost reductions, initiatives to improve unit prices, and improved profitability following the transfer of the CGM business, but was negatively affected by lower demand for electronic prescriptions, lower CRO revenue, U.S. tariffs, and the review of head office functions. Profit before tax was affected by a change from foreign exchange gains to foreign exchange losses, while profit attributable to owners of the parent was affected by the decline in profit before tax and tax expenses related to subsidiaries.
None. The notes regarding the going concern assumption state, “There are no applicable matters.”
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥364,403 million (YoY +0.8%) |
| Operating profit | ¥22,688 million (YoY +0.5%) |
| Ordinary income | ¥6,390 million (YoY -66.1%) |
| Profit attributable to owners of the parent | ¥492 million (YoY -95.3%) |
| Net income per share | ¥3.90 |
| Operating Margin | 6.2% |
| Equity ratio | End of the current fiscal period 29.8% / End of previous period 26.6% |
| Total assets | ¥542,510 million |
| Net assets | ¥160,880 million |
| Cash flows from operating activities | ¥42,458 million |
| Cash flows from investing activities | ¥-8,454 million |
| Cash flows from financing activities | ¥-39,821 million |
| Cash and cash equivalents at end of period | ¥39,820 million |
| Full-year earnings forecast | Net Sales ¥359,700 million (YoY -1.3%) / Operating profit ¥27,000 million (YoY +19.0%) / Income before taxes ¥22,000 million (YoY +244.3%) / Net income ¥15,400 million |
| Annual Dividend Forecast | ¥42 → ¥42（0.0%） |
| Payout ratio | 34.5% |
| Segment revenue | Diabetes Management ¥101,581 million (YoY +2.9%), Healthcare Solutions ¥128,389 million (YoY +0.1%), Diagnostics and Life Sciences ¥128,323 million (YoY -2.0%) |
| Segment profit | Diabetes Management ¥20,085 million (YoY +44.6%), Healthcare Solutions ¥6,234 million (YoY -32.8%), Diagnostics and Life Sciences ¥3,893 million (YoY -46.3%) |
| Regional sales | ¥154,577 million, ¥90,995 million, ¥75,032 million, ¥43,797 million |
| Depreciation and amortization | ¥27,119 million |
| Impairment loss | ¥-8 million |
| Disclosure regarding the going concern assumption | None. The notes regarding the going concern assumption state, “There are no applicable matters.” |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Not disclosed |
| Issued Shares at Period-End | 126,724,020 Shares |
| Treasury Shares at Period-End | 211,966 Shares |
| Factors Behind Changes in Business Performance | Revenue increased in Diabetes Management, driven by sales in the BGM business, favorable foreign exchange movements, and initiatives to improve unit prices and increase sales volume. In contrast, revenue declined in Diagnostics & Life Science due to stagnant market conditions, particularly in the United States. Operating profit benefited from solid sales in Diabetes Management, cost reductions, initiatives to improve unit prices, and improved profitability following the transfer of the CGM business, but was negatively affected by lower demand for electronic prescriptions, lower CRO revenue, U.S. tariffs, and the review of head office functions. Profit before tax was affected by a change from foreign exchange gains to foreign exchange losses, while profit attributable to owners of the parent was affected by the decline in profit before tax and tax expenses related to subsidiaries. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Operating profit benefited from solid sales in Diabetes Management, cost reductions, initiatives to improve unit prices, and improved profitability following the transfer of the CGM business, but was affected by lower revenue and profit in Healthcare Solutions and Diagnostics & Life Science, U.S. tariffs, and the review of head office functions. The substantial decline in profit before tax was mainly due to a change from a foreign exchange gain of ¥1,151 million in the previous fiscal year to a foreign exchange loss of ¥10,472 million in the current fiscal year. In addition to the decline in profit before tax, profit attributable to owners of the parent was affected by taxes associated with capital repayments by subsidiaries and the recognition of deferred tax liabilities related to dividends from subsidiaries.